190 related articles for article (PubMed ID: 33931971)
21. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
22. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
23. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
[TBL] [Abstract][Full Text] [Related]
24. Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.
van Dijk E; Biesma HD; Cordes M; Smeets D; Neerincx M; Das S; Eijk PP; Murphy V; Barat A; Bacon O; Prehn JHM; Betge J; Gaiser T; Fender B; Meijer GA; McNamara DA; Klinger R; Koopman M; Ebert MPA; Kay EW; Hennessey BT; Verheul HMW; Gallagher WM; O'Connor DP; Punt CJA; Loupakis F; Lambrechts D; Byrne AT; van Grieken NCT; Ylstra B
J Clin Oncol; 2018 Jul; 36(20):2052-2060. PubMed ID: 29792754
[TBL] [Abstract][Full Text] [Related]
25. Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity.
Kim TM; Jung SH; An CH; Lee SH; Baek IP; Kim MS; Park SW; Rhee JK; Lee SH; Chung YJ
Clin Cancer Res; 2015 Oct; 21(19):4461-72. PubMed ID: 25979483
[TBL] [Abstract][Full Text] [Related]
26. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
Del Rio M; Mollevi C; Bibeau F; Vie N; Selves J; Emile JF; Roger P; Gongora C; Robert J; Tubiana-Mathieu N; Ychou M; Martineau P
Eur J Cancer; 2017 May; 76():68-75. PubMed ID: 28284171
[TBL] [Abstract][Full Text] [Related]
27. A Qualitative Transcriptional Signature for Predicting Prognosis and Response to Bevacizumab in Metastatic Colorectal Cancer.
Yang J; Song K; Guo W; Zheng H; Fu Y; You T; Wang K; Qi L; Zhao W; Guo Z
Mol Cancer Ther; 2020 Jul; 19(7):1497-1505. PubMed ID: 32371582
[TBL] [Abstract][Full Text] [Related]
28. Chromosomal Aberrations Associated with Sequential Steps of the Metastatic Cascade in Colorectal Cancer Patients.
Joosse SA; Souche FR; Babayan A; Gasch C; Kerkhoven RM; Ramos J; Fabre JM; Riethdorf S; König A; Wikman H; Alix-Panabières C; Pantel K
Clin Chem; 2018 Oct; 64(10):1505-1512. PubMed ID: 30030273
[TBL] [Abstract][Full Text] [Related]
29. De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity.
Moosavi SH; Eide PW; Eilertsen IA; Brunsell TH; Berg KCG; Røsok BI; Brudvik KW; Bjørnbeth BA; Guren MG; Nesbakken A; Lothe RA; Sveen A
Genome Med; 2021 Sep; 13(1):143. PubMed ID: 34470666
[TBL] [Abstract][Full Text] [Related]
30. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.
Fumagalli D; Wilson TR; Salgado R; Lu X; Yu J; O'Brien C; Walter K; Huw LY; Criscitiello C; Laios I; Jose V; Brown DN; Rothé F; Maetens M; Zardavas D; Savas P; Larsimont D; Piccart-Gebhart MJ; Michiels S; Lackner MR; Sotiriou C; Loi S
Ann Oncol; 2016 Oct; 27(10):1860-6. PubMed ID: 27672107
[TBL] [Abstract][Full Text] [Related]
31. Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases.
Sakimura S; Nagayama S; Fukunaga M; Hu Q; Kitagawa A; Kobayashi Y; Hasegawa T; Noda M; Kouyama Y; Shimizu D; Saito T; Niida A; Tsuruda Y; Otsu H; Matsumoto Y; Uchida H; Masuda T; Sugimachi K; Sasaki S; Yamada K; Takahashi K; Innan H; Suzuki Y; Nakamura H; Totoki Y; Mizuno S; Ohshima M; Shibata T; Mimori K
PLoS Genet; 2021 Jan; 17(1):e1009113. PubMed ID: 33476333
[TBL] [Abstract][Full Text] [Related]
32. Latency and interval therapy affect the evolution in metastatic colorectal cancer.
Nikbakht H; Jessa S; Sukhai MA; Arseneault M; Zhang T; Letourneau L; Thomas M; Bourgey M; Roehrl MHA; Eveleigh R; Chen EX; Krzyzanowska M; Moore MJ; Giesler A; Yu C; Bedard PL; Kamel-Reid S; Majewski J; Siu LL; Riazalhosseini Y; Graham DM
Sci Rep; 2020 Jan; 10(1):581. PubMed ID: 31953485
[TBL] [Abstract][Full Text] [Related]
33. Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
Harada K; Okamoto W; Mimaki S; Kawamoto Y; Bando H; Yamashita R; Yuki S; Yoshino T; Komatsu Y; Ohtsu A; Sakamoto N; Tsuchihara K
BMC Cancer; 2019 Mar; 19(1):255. PubMed ID: 30898102
[TBL] [Abstract][Full Text] [Related]
34. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles.
Vignot S; Lefebvre C; Frampton GM; Meurice G; Yelensky R; Palmer G; Capron F; Lazar V; Hannoun L; Miller VA; André F; Stephens PJ; Soria JC; Spano JP
Eur J Cancer; 2015 May; 51(7):791-9. PubMed ID: 25797355
[TBL] [Abstract][Full Text] [Related]
35. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
36. Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab.
Li Z; Chen Y; Ren WU; Hu S; Tan Z; Wang Y; Chen Y; Zhang J; Wu J; Li T; Xu J; Ying X
Cancer Genomics Proteomics; 2019; 16(3):207-219. PubMed ID: 31018951
[TBL] [Abstract][Full Text] [Related]
37. The colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information.
Allen WL; Jithesh PV; Oliver GR; Proutski I; Longley DB; Lenz HJ; Proutski V; Harkin P; Johnston PG
BMC Cancer; 2010 Dec; 10():687. PubMed ID: 21172019
[TBL] [Abstract][Full Text] [Related]
38. Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasis.
Liu J; Cho YB; Hong HK; Wu S; Ebert PJ; Bray SM; Wong SS; Ting JC; Calley JN; Whittington CF; Bhagwat SV; Reinhard C; Wild R; Nam DH; Aggarwal A; Lee WY; Peng SB
Sci Rep; 2020 Jul; 10(1):10725. PubMed ID: 32612211
[TBL] [Abstract][Full Text] [Related]
39. A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.
Chen X; Qiu T; Zhu Y; Sun J; Li P; Wang B; Lin P; Cai X; Han X; Zhao F; Shu Y; Chang L; Jiang H; Gu Y
Oncologist; 2019 Jul; 24(7):883-e407. PubMed ID: 30877190
[TBL] [Abstract][Full Text] [Related]
40. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
